HALO logo
halo search icon
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc.
LXEO · NAS

Lexeo Therapeutics, Inc.

US$5.23

Price Arrow0.11 (2.15%)
21/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleEMA 125 BreakdownFakey Shakey - LongFakey Shakey - Long (Realtime)HALO AllHALO Consensus Value+2
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Lexeo Therapeutics, Inc. Overview

LXEO Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

About LXEO

icon

Website

Lexeo Therapeutics, Inc.

icon

Telephone

1.212.547.9879

icon

Address

6th floor, 345 Park Avenue South, New York, NY 10010

Description

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

LXEO Price Chart

Key Stats

Market Cap

US$402.03M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.51 - 10.99

Trade Value (12mth)

US$1,708,071.00

1 week

0.59%

1 month

-19.12%

YTD

-46.72%

1 year

66.23%

All time high

22.33

Key Fundamentals

EPS 3 yr Growth

-16.20%

EBITDA Margin

0.00%

Operating Cashflow

-$99m

Free Cash Flow Return

-52.40%

ROIC

-53.20%

Interest Coverage

-520.30

Quick Ratio

11.20

Other Data

Shares Outstanding (Fully Diluted)

81m

HALO Sector

Healthcare

Next Company Report Date

15-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

LXEO Announcements

Latest Announcements

DateAnnouncements
11 May 26
11 May 26
11 May 26
11 May 26
11 May 26

LXEO Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-2.49-3.09-1.86locklocklock
EPS (Fully Diluted)
$locklocklocklock-2.49-3.09-1.86locklocklock
Growth
%locklocklocklock-12-24.139.8locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Lexeo Therapeutics, Inc. (LXEO:NAS)?
Halo FAQ
The current share price of Lexeo Therapeutics, Inc. (LXEO:NAS) is USD$5.23.
What is the 52-week high share price for Lexeo Therapeutics, Inc. (LXEO:NAS)?
Halo FAQ
The 52-week high share price for Lexeo Therapeutics, Inc. (LXEO:NAS) is USD$10.99.
What is the 52-week low share price for Lexeo Therapeutics, Inc. (LXEO:NAS)?
Halo FAQ
The 52-week low share price for Lexeo Therapeutics, Inc. (LXEO:NAS) is USD$2.51.
What is the dividend yield for Lexeo Therapeutics, Inc. (LXEO:NAS)?
Halo FAQ
Lexeo Therapeutics, Inc. (LXEO:NAS) does not pay a dividend.
What was Lexeo Therapeutics, Inc. (LXEO:NAS) last dividend payment?
Halo FAQ
Lexeo Therapeutics, Inc. (LXEO:NAS) does not pay a dividend.
What is the franking level for Lexeo Therapeutics, Inc. (LXEO:NAS)?
Halo FAQ
Lexeo Therapeutics, Inc. (LXEO:NAS) has a franking level of 0.00%.
In which sector is Lexeo Therapeutics, Inc. (LXEO:NAS) classified?
Halo FAQ
Lexeo Therapeutics, Inc. (LXEO:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.